drugset / Trial / NCT04388189
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
RandomizedParallel-groupOpen-labelTreatment
Summary
The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupropion | Small molecule | 150 mg | — |
| Comparator | Bupropion | Small molecule | 450 mg | — |
| Subject | Duloxetine | Small molecule | 60 mg | — |